HomeMarket NewsMicro Cap StocksBreakthrough Data Leads to Surge in MediciNova Stock Prices!

Breakthrough Data Leads to Surge in MediciNova Stock Prices!

Actionable Trade Ideas

always free

mnov

MediciNova Inc’sΒ MNOV partners unveiled new data and findings from a Phase 2 clinical trial of MN-166 (ibudilast) in glioblastoma (GBM) patients at the Annual Meeting of theΒ Society for Neuro-Oncology.Β 

The primary objectives of this Phase 2 clinical trial were the safety and tolerability of MN-166 (ibudilast) and temozolomide (TMZ) combination treatment and the efficacy of the combination treatment defined as progression-free survival rate at six months using the RANO criteria.Β 

MN-166 (ibudilast) and TMZ combination treatment was safe and well-tolerated, and no unexpected adverse effects were reported.

The presentation also included data from preclinical studies that evaluated the combination of MN-166 (ibudilast) and anti-PD1 or anti-PD-L1 therapy in GBM models.

  • All subjects received TMZ and MN-166 (ibudilast) treatment. Progression-free survival at six months was 44% for new GBM and 31% for recurrent GBM.
  • CD3 expression was a good predictor for tumor progression at five months in recurrent glioblastoma subjects treated with MN-166 (ibudilast) and TMZ.

  • Median survival was extended to 66 days for the combination therapy of MN-166 (ibudilast) and anti-PD1 inhibitor treatment.
  • The addition of MN-166 (ibudilast) to the anti-PD-L1 inhibitor treatment significantly extended survival to a median of 34 days for the combination therapy.

Price Action:Β MNOV shares are up 14.3% at $2.04 on the last check Monday.

Photo Via Company


Swing Trading Ideas and Market Commentary

Need some new swing ideas? Get free weekly swing ideas and market commentary from Jonathan Bernstein here: Swing Trading.

Explore More

Weekly In-Depth Market Analysis and Actionable Trade Ideas

Get institutional-level analysis and trade ideas to take your trading to the next level, sign up for free and become apart of the community.